Kang C - Search Results

Year	Number of Results
1965	1
1969	2
1970	2
1971	1
1972	1
1973	4
1974	3
1975	2
1976	2
1977	5
1978	6
1979	2
1980	5
1981	8
1982	3
1983	2
1984	7
1985	9
1986	11
1987	10
1988	8
1989	7
1990	15
1991	13
1992	14
1993	19
1994	20
1995	17
1996	21
1997	22
1998	30
1999	36
2000	33
2001	43
2002	48
2003	77
2004	98
2005	98
2006	125
2007	145
2008	140
2009	177
2010	229
2011	269
2012	310
2013	347
2014	340
2015	361
2016	369
2017	335
2018	408
2019	426
2020	509
2021	618
2022	562
2023	502
2024	526
2025	445

1

Application of novel CAR technologies to improve treatment of autoimmune disease.

Cheever A, Kang CC, O'Neill KL, Weber KS. Cheever A, et al. Among authors: kang cc. Front Immunol. 2024 Oct 9;15:1465191. doi: 10.3389/fimmu.2024.1465191. eCollection 2024. Front Immunol. 2024. PMID: 39445021 Free PMC article. Review.

2

The AP2 transcription factor BARE RECEPTACLE regulates floral organogenesis via auxin pathways in woodland strawberry.

Lu R, Hu S, Feng J, Liu Z, Kang C. Lu R, et al. Among authors: kang c. Plant Cell. 2024 Oct 4;36(12):4970-87. doi: 10.1093/plcell/koae270. Online ahead of print. Plant Cell. 2024. PMID: 39367407 Free PMC article.

3

Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line.

Kang CH, Kim Y, Lee HK, Lee SM, Jeong HG, Choi SU, Park CH. Kang CH, et al. Int J Mol Sci. 2020 Dec 1;21(23):9163. doi: 10.3390/ijms21239163. Int J Mol Sci. 2020. PMID: 33271901 Free PMC article.

4

Reply by Authors.

Punjani N, Marinaro JA, Kang C, Gal J, Rippon B, Jotwani R, Weinberg R, Schlegel PN. Punjani N, et al. Among authors: kang c. J Urol. 2024 May;211(5):668. doi: 10.1097/JU.0000000000003908. Epub 2024 Mar 15. J Urol. 2024. PMID: 38488111 No abstract available.

5

Boosting transcriptional activities by employing repeated activation domains in transcription factors.

He C, Liang Y, Chen R, Shen Y, Li R, Sun T, Du X, Ni X, Shang J, He Y, Bao M, Luo H, Wang J, Liao P, Kang C, Yuan YW, Ning G. He C, et al. Among authors: kang c. Plant Cell. 2025 Feb 13;37(2):koae315. doi: 10.1093/plcell/koae315. Plant Cell. 2025. PMID: 39657052

6

CRISPR-Cas9 library screening combined with an exosome-targeted delivery system addresses tumorigenesis/TMZ resistance in the mesenchymal subtype of glioblastoma.

Zhao J, Cui X, Zhan Q, Zhang K, Su D, Yang S, Hong B, Wang Q, Ju J, Cheng C, Li C, Wan C, Wang Y, Zhou J, Kang C. Zhao J, et al. Among authors: kang c. Theranostics. 2024 Apr 29;14(7):2835-2855. doi: 10.7150/thno.92703. eCollection 2024. Theranostics. 2024. PMID: 38773970 Free PMC article.

7

Regulation of senescence-associated secretory phenotypes in osteoarthritis by cytosolic UDP-GlcNAc retention and O-GlcNAcylation.

Kang D, Lee J, Yook G, Jeong S, Shin J, Kim MS, Kim YJ, Jung H, Ahn J, Kim TW, Chang MJ, Chang CB, Kang SB, Yang WH, Lee YH, Cho JW, Yi EC, Kang C, Kim JH. Kang D, et al. Among authors: kang c. Nat Commun. 2025 Feb 4;16(1):1094. doi: 10.1038/s41467-024-55085-1. Nat Commun. 2025. PMID: 39904978 Free PMC article.

8

Proteogenomic characterization of molecular and cellular targets for treatment-resistant subtypes in locally advanced cervical cancers.

Hyeon DY, Nam D, Shin HJ, Jeong J, Jung E, Cho SY, Shin DH, Ku JL, Baek HJ, Yoo CW, Hong EK, Lim MC, Lee SJ, Bae YK, Kim JK, Bae J, Choi W, Kim SJ, Back S, Kang C, Madar IH, Kim H, Kim S, Kim DK, Kang J, Park GW, Park KS, Shin Y, Kim SS, Jung K, Hwang D, Lee SW, Kim JY. Hyeon DY, et al. Among authors: kang c. Mol Cancer. 2025 Mar 14;24(1):77. doi: 10.1186/s12943-025-02256-3. Mol Cancer. 2025. PMID: 40087745 Free PMC article.

9

Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.

Yang Z, Li Z, Zhan Y, Lin Z, Fang Z, Xu X, Lin L, Li H, Lin Z, Kang C, Liang J, Liang S, Li Y, Li S, Yang X, Ye F, Zhong N; Onradivir Trial Recruitment and Medical Monitoring Group. Yang Z, et al. Among authors: kang c. Lancet Infect Dis. 2024 May;24(5):535-545. doi: 10.1016/S1473-3099(23)00743-0. Epub 2024 Feb 5. Lancet Infect Dis. 2024. PMID: 38330975 Clinical Trial.

10

ADAM12 promotes temozolomide resistance in glioblastoma by activating the TNF-α - NF-κB pathway.

Cheng C, Cui L, Cui X, Zhan Q, Ju J, Hong B, Huang Y, Ding Y, Xu H, Qiu T, Kang C, Liu X, Wang Q, Zeng L. Cheng C, et al. Among authors: kang c. Cancer Lett. 2025 Jun 28;620:217684. doi: 10.1016/j.canlet.2025.217684. Epub 2025 Apr 1. Cancer Lett. 2025. PMID: 40180114

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,930 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,930 results

Results by year